Business Context and Reporting Period
This Form 8-K filing by BioRestorative Therapies, Inc. (Delaware) reports events occurring on August 5, 2016. The company is a biotechnology firm headquartered in Melville, New York. The filing specifically addresses the creation of direct financial obligations through two new promissory notes.
Key Financial Metrics and Obligations
The filing details two distinct debt instruments issued on August 5, 2016:
- Director Loan (Catell Note): Principal amount of $100,000 borrowed from director Robert Catell. Interest rate is 10% per annum, maturing February 5, 2017. The company issued a warrant for 8,000 shares at $4.00 per share as consideration.
- Non-Affiliated Loan (Lender Note): Principal amount of $242,000 issued for cash consideration of $200,000. The note is non-interest bearing unless an event of default occurs, maturing February 4, 2017. It includes prepayment discounts and acceleration clauses.
The filing does not provide current revenue, profit, cash flow, or overall liquidity metrics.
Material Changes and Terms
The primary material change is the incurrence of $342,000 in total principal debt obligations. Key terms include:
- Prepayment Rights: The Catell Note allows for mandatory prepayment if the company raises $10,000,000 in a single financing event prior to maturity. The Lender Note allows the company to prepay at a discount ($20,000 or $10,000) depending on the timing of repayment.
- Default Consequences: The Lender Note is subject to acceleration upon a change in control or other default events. In such cases, the company must pay 110% of the outstanding principal plus interest and fees.
- Related Party Transactions: The filing notes that between March and May 2016, Director Catell purchased 50,000 shares at $4.00 per share and received warrants for 50,000 shares at $5.00 per share.
Guidance, Risks, and Contingencies
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the contractual terms of the debt. The primary contingency identified is the potential acceleration of the Lender Note debt in the event of a default or change in control, which would increase the repayment obligation to 110% of the principal.
Investor Verification Checklist
- Verify the company's current cash position to assess ability to service the $342,000 in new debt maturing in February 2017.
- Confirm whether the company has initiated any equity or debt financing rounds that could trigger the mandatory prepayment of the Catell Note.
- Review the company's capitalization table to understand the dilution impact of the 8,000 new warrants issued to the director.
- Assess the likelihood of a change in control or default event that would trigger the 110% penalty on the Lender Note.